Skip to main content
SpringerLink
Log in

Dietary and Lifestyle Cardiometabolic Risk Reduction Strategies in Pro-inflammatory Diseases

  • Chapter
  • First Online:
Prevention and Treatment of Cardiovascular Disease

Part of the book series: Contemporary Cardiology ((CONCARD))

Abstract

Systemic inflammatory and autoimmune conditions including psoriasis, inflammatory arthritis, systemic lupus erythematosus, inflammatory bowel disease, and human immunodeficiency virus create a predisposition to early onset atherosclerosis and cardiovascular events. In this chapter, we discuss the impact systemic inflammation has on the development of atherosclerosis with a specific emphasis on pro-inflammatory and autoimmune conditions and how dietary and lifestyle modification may help mitigate cardiovascular risk. Given the breadth of the topic at hand, it is not possible for this chapter to be all encompassing, but rather we aim to provide a general framework on how to approach cardiovascular risk stratification in pro-inflammatory populations, with special emphasis on the role of dietary and lifestyle modifications.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Chaplin DD. Overview of the immune response. J Allergy Clin Immunol. 2010;125:S3–23.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Garshick MS. Editorial commentary: psoriasis, inflammation and cardiometabolic disease. Will we ever get to the heart of the matter? Trends Cardiovasc Med. 2020;30:479–480.

    Google Scholar 

  3. Hansson GK. Immune and inflammatory mechanisms in the development of atherosclerosis. Br Heart J. 1993;69:S38–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Arnett DK, Blumenthal RS, Albert MA et al. ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019;74:1376–1414.

    Google Scholar 

  5. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473:317–25.

    Article  CAS  PubMed  Google Scholar 

  6. Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol. 2012;32:2045–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Kaptoge S, Seshasai SR, Gao P, Freitag DF, Butterworth AS, Borglykke A, Di Angelantonio E, Gudnason V, Rumley A, Lowe GD, Jorgensen T, Danesh J. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J. 2014;35:578–89. https://doi.org/10.1093/eurheartj/eht367.

    Article  CAS  PubMed  Google Scholar 

  8. Back M, Yurdagul A Jr, Tabas I, Oorni K, Kovanen PT. Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities. Nat Rev Cardiol. 2019;16:389–406.

    PubMed  PubMed Central  Google Scholar 

  9. Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119–31.

    Article  CAS  PubMed  Google Scholar 

  10. Tousoulis D, Oikonomou E, Economou EK, Crea F, Kaski JC. Inflammatory cytokines in atherosclerosis: current therapeutic approaches. Eur Heart J. 2016;37:1723–32.

    Article  CAS  PubMed  Google Scholar 

  11. Crowson CS, Matteson EL, Myasoedova E, Michet CJ, Ernste FC, Warrington KJ, Davis JM 3rd, Hunder GG, Therneau TM, Gabriel SE. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum. 2011;63:633–9.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, Kavanaugh A, McInnes IB, Solomon DH, Strand V, Yamamoto K. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001.

    Article  PubMed  Google Scholar 

  13. Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59:1690–7.

    Article  PubMed  Google Scholar 

  14. Geraldino-Pardilla L, Zartoshti A, Ozbek AB, Giles JT, Weinberg R, Kinkhabwala M, Bokhari S, Bathon JM. Arterial inflammation detected with (18) F-fluorodeoxyglucose-positron emission tomography in rheumatoid arthritis. Arthritis Rheumatol. 2018;70:30–9.

    Article  CAS  PubMed  Google Scholar 

  15. Amezaga Urruela M, Suarez-Almazor ME. Lipid paradox in rheumatoid arthritis: changes with rheumatoid arthritis therapies. Curr Rheumatol Rep. 2012;14:428–37.

    Article  CAS  PubMed  Google Scholar 

  16. Scott IC, Hider SL, Scott DL. Thromboembolism with Janus Kinase (JAK) inhibitors for rheumatoid arthritis: how real is the risk? Drug Saf. 2018;41:645–53.

    Article  CAS  PubMed  Google Scholar 

  17. Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update. Ann Rheum Dis. 2017;76:17–28.

    Article  CAS  PubMed  Google Scholar 

  18. Kerekes G, Nurmohamed MT, Gonzalez-Gay MA, Seres I, Paragh G, Kardos Z, Barath Z, Tamasi L, Soltesz P, Szekanecz Z. Rheumatoid arthritis and metabolic syndrome. Nat Rev Rheumatol. 2014;10:691–6.

    Article  CAS  PubMed  Google Scholar 

  19. Chang K, Yang SM, Kim SH, Han KH, Park SJ, Shin JI. Smoking and rheumatoid arthritis. Int J Mol Sci. 2014;15:22279–95.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Burghardt RD, Kazim MA, Ruther W, Niemeier A, Strahl A. The impact of physical activity on serum levels of inflammatory markers in rheumatoid arthritis: a systematic literature review. Rheumatol Int. 2019;39:793–804.

    Article  CAS  PubMed  Google Scholar 

  21. Rausch Osthoff AK, Niedermann K, Braun J, et al. 2018 EULAR recommendations for physical activity in people with inflammatory arthritis and osteoarthritis. Ann Rheum Dis. 2018;77:1251–60.

    Article  PubMed  Google Scholar 

  22. Khanna S, Jaiswal KS, Gupta B. Managing rheumatoid arthritis with dietary interventions. Front Nutr. 2017;4:52.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  23. Greb JE, Goldminz AM, Elder JT, Lebwohl MG, Gladman DD, Wu JJ, Mehta NN, Finlay AY, Gottlieb AB. Psoriasis. Nat Rev Dis Primers. 2016;2:16082.

    Article  PubMed  Google Scholar 

  24. Miller IM, Ellervik C, Yazdanyar S, Jemec GB. Meta-analysis of psoriasis, cardiovascular disease, and associated risk factors. J Am Acad Dermatol. 2013;69:1014–24.

    Article  PubMed  Google Scholar 

  25. Garshick MS, Barrett T, Wechter T, Azarchi S, Scher J, Neimann A, Katz S, Fuentes-Duculan J, Cannizzaro MV, Jelic S, Fisher EA, Krueger JG, Berger JS. Inflammasome signaling and impaired vascular health in psoriasis. Arterioscler Thromb Vasc Biol. 2019;39(4):787–98.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Wang Y, Golden JB, Fritz Y, Zhang X, Diaconu D, Camhi MI, Gao H, Dawes SM, Xing X, Ganesh SK, Gudjonsson JE, Simon DI, McCormick TS, Ward NL. Interleukin 6 regulates psoriasiform inflammation-associated thrombosis. JCI Insight. 2016;1:e89384.

    PubMed  PubMed Central  Google Scholar 

  27. Mehta NN, Teague HL, Swindell WR, et al. IFN-gamma and TNF-alpha synergism may provide a link between psoriasis and inflammatory atherogenesis. Sci Rep. 2017;7:13831.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  28. Armstrong AW, Voyles SV, Armstrong EJ, Fuller EN, Rutledge JC. A tale of two plaques: convergent mechanisms of T-cell-mediated inflammation in psoriasis and atherosclerosis. Exp Dermatol. 2011;20:544–9.

    Article  CAS  PubMed  Google Scholar 

  29. Teague HL, Aksentijevich M, Stansky E, et al. Cells of myeloid origin partly mediate the association between psoriasis severity and coronary plaque. J Invest Dermatol. 2020;140:912–915 e1.

    Google Scholar 

  30. Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB, Gelfand JM. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol. 2006;55:829–35.

    Article  PubMed  Google Scholar 

  31. Kunz M, Simon JC, Saalbach A. Psoriasis: obesity and fatty acids. Front Immunol. 2019;10:1807.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Rivers JP, Powell-Wiley TM, Dey AK, et al. Visceral adiposity in psoriasis is associated with vascular inflammation by (18)F-fluorodeoxyglucose positron-emission tomography/computed tomography beyond cardiometabolic disease risk factors in an observational cohort study. JACC Cardiovasc Imaging. 2018;11:349–57.

    Article  PubMed  Google Scholar 

  33. Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80(4):1073–113.

    Article  PubMed  Google Scholar 

  34. Naldi L. Psoriasis and smoking: links and risks. Psoriasis (Auckl). 2016;6:65–71.

    Google Scholar 

  35. Alotaibi HA. Effects of weight loss on psoriasis: a review of clinical trials. Cureus. 2018;10:e3491.

    PubMed  PubMed Central  Google Scholar 

  36. Ko SH, Chi CC, Yeh ML, Wang SH, Tsai YS, Hsu MY. Lifestyle changes for treating psoriasis. Cochrane Database Syst Rev. 2019;7:CD011972.

    PubMed  Google Scholar 

  37. Li W, Han J, Choi HK, Qureshi AA. Smoking and risk of incident psoriasis among women and men in the United States: a combined analysis. Am J Epidemiol. 2012;175:402–13.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Ford AR, Siegel M, Bagel J, et al. Dietary recommendations for adults with psoriasis or psoriatic arthritis from the medical board of the national psoriasis foundation: a systematic review. JAMA Dermatol. 2018;154:934–50.

    Article  PubMed  Google Scholar 

  39. Kahlenberg JM, Kaplan MJ. The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus. Arthritis Res Ther. 2011;13:203.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Izmirly PM, Wan I, Sahl S, et al. The incidence and prevalence of systemic lupus erythematosus in New York county (Manhattan), New York: the Manhattan lupus surveillance program. Arthritis Rheumatol. 2017;69:2006–17.

    Article  PubMed  Google Scholar 

  41. Tsokos GC, Lo MS, Costa Reis P, Sullivan KE. New insights into the immunopathogenesis of systemic lupus erythematosus. Nat Rev Rheumatol. 2016;12:716–30.

    Article  CAS  PubMed  Google Scholar 

  42. Danila MI, Pons-Estel GJ, Zhang J, Vila LM, Reveille JD, Alarcon GS. Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. Rheumatology (Oxford). 2009;48:542–5.

    Article  Google Scholar 

  43. Katz G, Smilowitz NR, Blazer A, Clancy R, Buyon JP, Berger JS. Systemic lupus erythematosus and increased prevalence of atherosclerotic cardiovascular disease in hospitalized patients. Mayo Clin Proc. 2019;94:1436–43.

    Article  PubMed  Google Scholar 

  44. Tselios K, Sheane BJ, Gladman DD, Urowitz MB. Optimal monitoring for coronary heart disease risk in patients with systemic lupus erythematosus: a systematic review. J Rheumatol. 2016;43:54–65.

    Article  CAS  PubMed  Google Scholar 

  45. Petri MA, Barr E, Magder LS. Development of a systemic lupus erythematosus cardiovascular risk equation. Lupus Sci Med. 2019;6:e000346.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Ramji DP, Davies TS. Cytokines in atherosclerosis: key players in all stages of disease and promising therapeutic targets. Cytokine Growth Factor Rev. 2015;26:673–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Boulos D, Koelmeyer RL, Morand EF, Hoi AY. Cardiovascular risk profiles in a lupus cohort: what do different calculators tell us? Lupus Sci Med. 2017;4:e000212.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Masson W, Rossi E, Mora-Crespo LM, Cornejo-Pena G, Pessio C, Gago M, Alvarado RN, Scolnik M. Cardiovascular risk stratification and appropriate use of statins in patients with systemic lupus erythematosus according to different strategies. Clin Rheumatol. 2020;39:455–62.

    Article  PubMed  Google Scholar 

  49. Sivakumaran J, Harvey P, Omar A, Urowitz MB, Gladman DD, Anderson N, Su J, Touma Z. 291 assessment of the QRISK2, QRISK3, SLE cardiovascular risk equation, modified Framingham and Framingham risk calculators as predictors of cardiovascular disease events in systemic lupus erythematosus. Lupus Sci Med. 2019;6:A211–2.

    Google Scholar 

  50. Andrades C, Fuego C, Manrique-Arija S, Fernandez-Nebro A. Management of cardiovascular risk in systemic lupus erythematosus: a systematic review. Lupus. 2017;26:1407–19.

    Article  CAS  PubMed  Google Scholar 

  51. Rodriguez Huerta MD, Trujillo-Martin MM, Rua-Figueroa I, Cuellar-Pompa L, Quiros-Lopez R, Serrano-Aguilar P, Spanish SLE CPG Development Group. Healthy lifestyle habits for patients with systemic lupus erythematosus: a systemic review. Semin Arthritis Rheum. 2016;45:463–70.

    Article  PubMed  Google Scholar 

  52. Barnes JN, Nualnim N, Dhindsa M, Renzi CP, Tanaka H. Macro- and microvascular function in habitually exercising systemic lupus erythematosus patients. Scand J Rheumatol. 2014;43:209–16.

    Article  CAS  PubMed  Google Scholar 

  53. Bruce IN, O’Keeffe AG, Farewell V, et al. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the systemic lupus international collaborating clinics (SLICC) inception cohort. Ann Rheum Dis. 2015;74:1706–13.

    Article  CAS  PubMed  Google Scholar 

  54. Tselios K, Koumaras C, Gladman DD, Urowitz MB. Dyslipidemia in systemic lupus erythematosus: just another comorbidity? Semin Arthritis Rheum. 2016;45:604–10.

    Article  CAS  PubMed  Google Scholar 

  55. Ballocca F, D’Ascenzo F, Moretti C, Omede P, Cerrato E, Barbero U, Abbate A, Bertero MT, Zoccai GB, Gaita F. Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis. Eur J Prev Cardiol. 2015;22:1435–41.

    Article  PubMed  Google Scholar 

  56. Elkan AC, Anania C, Gustafsson T, Jogestrand T, Hafstrom I, Frostegard J. Diet and fatty acid pattern among patients with SLE: associations with disease activity, blood lipids and atherosclerosis. Lupus. 2012;21:1405–11.

    Article  PubMed  CAS  Google Scholar 

  57. Lertratanakul A, Wu P, Dyer A, et al. 25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort. Arthritis Care Res (Hoboken). 2014;66:1167–76.

    Article  CAS  Google Scholar 

  58. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Benchimol EI, Panaccione R, Ghosh S, Wu JCY, Chan FKL, Sung JJY, Kaplan GG. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 2018;390:2769–78.

    Article  Google Scholar 

  59. Guan Q. A comprehensive review and update on the pathogenesis of inflammatory bowel disease. J Immunol Res. 2019;2019:7247238.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  60. Rawla P, Sunkara T, Raj JP. Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives. J Inflamm Res. 2018;11:215–26.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Bunu DM, Timofte CE, Ciocoiu M, Floria M, Tarniceriu CC, Barboi OB, Tanase DM. Cardiovascular manifestations of inflammatory bowel disease: pathogenesis, diagnosis, and preventive strategies. Gastroenterol Res Pract. 2019;2019:3012509.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Zezos P, Kouklakis G, Saibil F. Inflammatory bowel disease and thromboembolism. World J Gastroenterol. 2014;20:13863–78.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Feng W, Chen G, Cai D, Zhao S, Cheng J, Shen H. Inflammatory bowel disease and risk of ischemic heart disease: an updated meta-analysis of cohort studies. J Am Heart Assoc. 2017;6:e005892.

    PubMed  PubMed Central  Google Scholar 

  64. Singh S, Dulai PS, Zarrinpar A, Ramamoorthy S, Sandborn WJ. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2017;14:110–21.

    Article  CAS  PubMed  Google Scholar 

  65. Aarestrup J, Jess T, Kobylecki CJ, Nordestgaard BG, Allin KH. Cardiovascular risk profile among patients with inflammatory bowel disease: a population-based study of more than 100 000 individuals. J Crohns Colitis. 2019;13:319–23.

    Article  PubMed  Google Scholar 

  66. Schicho R, Marsche G, Storr M. Cardiovascular complications in inflammatory bowel disease. Curr Drug Targets. 2015;16:181–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Nos P, Domenech E. Management of Crohn’s disease in smokers: is an alternative approach necessary? World J Gastroenterol. 2011;17:3567–74.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Jones PD, Kappelman MD, Martin CF, Chen W, Sandler RS, Long MD. Exercise decreases risk of future active disease in patients with inflammatory bowel disease in remission. Inflamm Bowel Dis. 2015;21:1063–71.

    Article  PubMed  Google Scholar 

  69. Rizzello F, Spisni E, Giovanardi E, Imbesi V, Salice M, Alvisi P, Valerii MC, Gionchetti P. Implications of the westernized diet in the onset and progression of IBD. Nutrients. 2019;11:1033.

    Article  CAS  PubMed Central  Google Scholar 

  70. Amre DK, D’Souza S, Morgan K, et al. Imbalances in dietary consumption of fatty acids, vegetables, and fruits are associated with risk for Crohn’s disease in children. Am J Gastroenterol. 2007;102:2016–25.

    Article  CAS  PubMed  Google Scholar 

  71. Levine A, Rhodes JM, Lindsay JO, et al. Dietary guidance from the international organization for the study of inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2020;18:1381–92.

    Article  PubMed  Google Scholar 

  72. Rocha R, Santana GO, Almeida N, Lyra AC. Analysis of fat and muscle mass in patients with inflammatory bowel disease during remission and active phase. Br J Nutr. 2009;101:676–9.

    Article  CAS  PubMed  Google Scholar 

  73. Nguyen GC, Munsell M, Harris ML. Nationwide prevalence and prognostic significance of clinically diagnosable protein-calorie malnutrition in hospitalized inflammatory bowel disease patients. Inflamm Bowel Dis. 2008;14:1105–11.

    Article  PubMed  Google Scholar 

  74. Feinstein MJ, Hsue PY, Benjamin LA, Bloomfield GS, Currier JS, Freiberg MS, Grinspoon SK, Levin J, Longenecker CT, Post WS. Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association. Circulation. 2019;140:e98–e124.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Somsouk M, Estes JD, Deleage C, Dunham RM, Albright R, Inadomi JM, Martin JN, Deeks SG, McCune JM, Hunt PW. Gut epithelial barrier and systemic inflammation during chronic HIV infection. AIDS. 2015;29:43–51.

    Article  CAS  PubMed  Google Scholar 

  76. Moir S, Fauci AS. B cells in HIV infection and disease. Nat Rev Immunol. 2009;9:235–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Teigler JE, Leyre L, Chomont N, et al. Distinct biomarker signatures in HIV acute infection associate with viral dynamics and reservoir size. JCI Insight. 2018;3:e98420.

    Article  PubMed Central  Google Scholar 

  78. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Neuhaus J, Nixon D, Paton NI, Neaton JD, Group ISS. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 2008;5:e203.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  79. Nou E, Lo J, Grinspoon SK. Inflammation, immune activation, and cardiovascular disease in HIV. AIDS. 2016;30:1495–509.

    Article  CAS  PubMed  Google Scholar 

  80. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary. Circulation. 2019;140(11):e563–95.

    PubMed  PubMed Central  Google Scholar 

  81. Capili B, Anastasi JK, Chang M, Ogedegbe O. Barriers and facilitators to engagement in lifestyle interventions among individuals with HIV. J Assoc Nurses AIDS Care. 2014;25:450–7.

    Article  PubMed  PubMed Central  Google Scholar 

  82. d’Ettorre G, Ceccarelli G, Giustini N, Mastroianni CM, Silvestri G, Vullo V. Taming HIV-related inflammation with physical activity: a matter of timing. AIDS Res Hum Retrovir. 2014;30:936–44.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Botros D, Somarriba G, Neri D, Miller TL. Interventions to address chronic disease and HIV: strategies to promote exercise and nutrition among HIV-infected individuals. Curr HIV/AIDS Rep. 2012;9:351–63.

    Article  PubMed  PubMed Central  Google Scholar 

  84. Poudel-Tandukar K, Chandyo RK. Dietary B vitamins and serum C-reactive protein in persons with human immunodeficiency virus infection: the positive living with HIV (POLH) study. Food Nutr Bull. 2016;37:517–28.

    Article  PubMed  Google Scholar 

  85. Fields-Gardner C, Campa A, American Dietetics Association. Position of the American Dietetic Association: nutrition intervention and human immunodeficiency virus infection. J Am Diet Assoc. 2010;110:1105–19.

    Article  PubMed  Google Scholar 

  86. Lazzaretti RK, Kuhmmer R, Sprinz E, Polanczyk CA, Ribeiro JP. Dietary intervention prevents dyslipidemia associated with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected individuals: a randomized trial. J Am Coll Cardiol. 2012;59:979–88.

    Article  CAS  PubMed  Google Scholar 

  87. Tsiodras S, Poulia KA, Yannakoulia M, Chimienti SN, Wadhwa S, Karchmer AW, Mantzoros CS. Adherence to Mediterranean diet is favorably associated with metabolic parameters in HIV-positive patients with the highly active antiretroviral therapy-induced metabolic syndrome and lipodystrophy. Metabolism. 2009;58:854–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Oliveira JM, Rondo PH. Omega-3 fatty acids and hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: systematic review and meta-analysis. HIV Clin Trials. 2011;12:268–74.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, Department of Medicine, New York University Langone Health, New York, NY, USA

    Ashira Blazer

  2. Leon H. Charney Division of Cardiology, Department of Medicine, New York University Langone Health, New York, NY, USA

    Kinjan Parikh & Michael S. Garshick

  3. Division of Digestive and Liver Diseases, Department of Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA

    David I. Fudman

  4. Center for the Prevention of Cardiovascular Disease, New York University Langone Health, New York, NY, USA

    Michael S. Garshick

Authors
  1. Ashira Blazer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kinjan Parikh
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David I. Fudman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Michael S. Garshick
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael S. Garshick .

Editor information

Editors and Affiliations

  1. Division of Cardiovascular Medicine, Department of Medicine, University of California San Diego, San Diego, CA, USA

    Michael J. Wilkinson

  2. Center for the Prevention of Cardiovascular Disease and Leon H. Charney Division of Cardiology, Department of Medicine, New York University Langone Health, New York, NY, USA

    Michael S. Garshick

  3. Division of Cardiovascular Medicine, Department of Medicine, University of California San Diego, San Diego, CA, USA

    Pam R. Taub

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Blazer, A., Parikh, K., Fudman, D.I., Garshick, M.S. (2021). Dietary and Lifestyle Cardiometabolic Risk Reduction Strategies in Pro-inflammatory Diseases. In: Wilkinson, M.J., Garshick, M.S., Taub, P.R. (eds) Prevention and Treatment of Cardiovascular Disease. Contemporary Cardiology. Humana, Cham. https://doi.org/10.1007/978-3-030-78177-4_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-78177-4_12

  • Published:

  • Publisher Name: Humana, Cham

  • Print ISBN: 978-3-030-78176-7

  • Online ISBN: 978-3-030-78177-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation